+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Acute On Chronic Liver Failure (ACLF) - Pipeline Insight, 2024

  • PDF Icon

    Clinical Trials

  • 60 Pages
  • June 2024
  • Region: Global
  • DelveInsight
  • ID: 4934521
This “Acute On Chronic Liver Failure (ACLF) - Pipeline Insight, 2024” report provides comprehensive insights about 4+ companies and 6+ pipeline drugs in Acute On Chronic Liver Failure (ACLF) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Acute On Chronic Liver Failure (ACLF): Understanding

Acute On Chronic Liver Failure (ACLF): Overview

Acute on chronic liver failure is a clinical syndrome of sudden hepatic decompensation observed in patients with pre-existing chronic liver disease. Acute on chronic liver failure is a serious condition with very high morbidity and mortality.

The pathophysiology is based on the understanding that an acute precipitating event in a patient with a chronic liver condition that injures hepatocytes leads to the accumulation of a cascade of inflammatory cytokines and results in further hepatic injury in the presence of failure of hepatocyte regeneration. The resulting compromise in immune function and liver decompensation leads to further susceptibility to infections, multi-organ failure, and death.
Patients will have features of acute hepatic decompensation. Also common are prolonged INR greater than or equal to 1.5, often elevated bilirubin and aminotransferases, thrombocytopenia with anemia, hypoglycemia, elevated ammonia, features of acute renal injury (with elevated serum creatinine), and abnormal electrolytes (hypokalemia, hypophosphatemia). Any imaging to support the clinical examination findings and ascertain infection or any organ involvement or organ failure may be required. Imaging of the brain, chest, abdomen, and pelvis should be considered. Abdominal imaging to determine the presence of features of portal hypertension, hepatocellular carcinoma, vascular thrombosis, lymph nodes, and spleen is vital. Abdominal sonogram with Doppler could be considered in patients with concomitant renal injury and vascular thrombosis. Brain imaging (CT or MRI) is helpful to rule out organic etiology of altered mental status, while chest imaging will help rule out pulmonary edema or pneumonia.

The management of ACLF consists of the prevention of precipitating factors leading to acute hepatic decompensation, supportive care, and early initiation of specific therapy, prevention, and management of complications. It also includes determining the prognosis and the need for liver support including possible liver transplantation. All patients should be hospitalized preferably at a center that has facilities and expertise for a liver transplant.

"Acute On Chronic Liver Failure (ACLF)- Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute On Chronic Liver Failure (ACLF) pipeline landscape is provided which includes the disease overview and Acute On Chronic Liver Failure (ACLF) treatment guidelines. The assessment part of the report embraces, in depth Acute On Chronic Liver Failure (ACLF) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute On Chronic Liver Failure (ACLF) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Acute On Chronic Liver Failure (ACLF) R&D. The therapies under development are focused on novel approaches to treat/improve Acute On Chronic Liver Failure (ACLF).

Acute On Chronic Liver Failure (ACLF) Emerging Drugs Chapters

This segment of the Acute On Chronic Liver Failure (ACLF) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acute On Chronic Liver Failure (ACLF) Emerging Drugs

HepaStem: Cellaion SA

HepaStem acts directly on the cells making up the inflammatory reaction and on the signaling pathways of hepatic regeneration. By restoring liver function, secondary failures of other organs also recover their functional capacity. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Acute On Chronic Liver Failure (ACLF).

F573: Beijing Continent Pharmaceutical Co, Ltd.

F573 is a proprietary di-peptide small molecule compound with potent inhibitory effect on caspases, a class of enzymes critical for cell death and inflammatory response. Promising efficacy has also been shown in animal studies for liver failure, brain ischemia, and myocardial infarction. In toxicology studies in dogs and rats, F573 also demonstrated an excellent safety profile. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Acute On Chronic Liver Failure (ACLF).

Acute On Chronic Liver Failure (ACLF): Therapeutic Assessment

This segment of the report provides insights about the different Acute On Chronic Liver Failure (ACLF) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Acute On Chronic Liver Failure (ACLF)

  • There are approx. 4+ key companies which are developing the therapies for Acute On Chronic Liver Failure (ACLF). The companies which have their Acute On Chronic Liver Failure (ACLF) drug candidates in the most advanced stage, i.e. Phase II include, Cellaion SA.

Phases

This report covers around 6+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

Route of Administration

Acute On Chronic Liver Failure (ACLF) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acute On Chronic Liver Failure (ACLF): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute On Chronic Liver Failure (ACLF) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute On Chronic Liver Failure (ACLF) drugs.

Acute On Chronic Liver Failure (ACLF) Report Insights

  • Acute On Chronic Liver Failure (ACLF) Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Acute On Chronic Liver Failure (ACLF) Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Acute On Chronic Liver Failure (ACLF) drugs?
  • How many Acute On Chronic Liver Failure (ACLF) drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute On Chronic Liver Failure (ACLF)?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Acute On Chronic Liver Failure (ACLF) therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Acute On Chronic Liver Failure (ACLF) and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Cellaion SA
  • Beijing Continent Pharmaceutical Co, Ltd.
  • Grifols Therapeutics LLC

Key Products

  • HepaStem
  • F573
  • PE-A 5%


This product will be delivered within 2 business days.

Table of Contents

IntroductionExecutive Summary
Acute On Chronic Liver Failure (ACLF): Overview
  • Introduction
  • Causes
  • Pathophysiology
  • Signs and Symptoms
  • Diagnosis
  • Treatment
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Acute On Chronic Liver Failure (ACLF)- Analytical Perspective
Late Stage Products (Phase III)
  • Comparative Analysis
Drug name: Company name
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
HepaStem: Cellaion SA
  • Product Description
  • Research and Development
  • Product Development Activities
Early Stage Products (Phase I)
  • Comparative Analysis
Drug name: Company name
  • Product Description
  • Research and Development
  • Product Development Activities
Preclinical and Discovery Stage Products
  • Comparative Analysis
Drug name: Company name
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Acute On Chronic Liver Failure (ACLF) Key CompaniesAcute On Chronic Liver Failure (ACLF) Key ProductsAcute On Chronic Liver Failure (ACLF)- Unmet NeedsAcute On Chronic Liver Failure (ACLF)- Market Drivers and BarriersAcute On Chronic Liver Failure (ACLF)- Future Perspectives and ConclusionAcute On Chronic Liver Failure (ACLF) Analyst ViewsAcute On Chronic Liver Failure (ACLF) Key CompaniesAppendix
List of Tables
Table 1 Total Products for Acute On Chronic Liver Failure (ACLF)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Acute On Chronic Liver Failure (ACLF)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Cellaion SA
  • Beijing Continent Pharmaceutical Co, Ltd.
  • Grifols Therapeutics LLC